Cover Image

CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2

CoronaVac, also known as the Sinovac inactivated SARS-CoV-2 vaccine, has been widely implemented in combating the COVID-19 pandemic. We summarized the results of clinical trials and real-world studies of CoronaVac in this review. The overall efficacy for the prevention of symptomatic COVID-19 (befor...

Full description

Saved in:

Bibliographic Details
Main Authors:	Lairun Jin (Author), Zhuopei Li (Author), Xiaoyin Zhang (Author), Jingxin Li (Author), Fengcai Zhu (Author)
Format:	Book
Published:	Taylor & Francis Group, 2022-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers
by: Ahmet Soysal, et al.
Published: (2021)

Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial
by: Dandan Zhu, et al.
Published: (2022)

Immunogenicity and safety of an inactivated COVID-19 vaccine (CoronaVac®) co-administered with an inactivated enterovirus type 71 vaccine (Inlive®): A phase 4, randomized, controlled trial
by: Yajun Shu, et al.
Published: (2024)

The impact of previous SARS-CoV-2 infection on post-vaccine adverse events in individuals vaccinated with TURKOVAC or CoronaVac -inactivated COVID-19 vaccines
by: Mine Durusu Tanriover, et al.
Published: (2024)

ANCA-associated vasculitis following the CoronaVac vaccination
by: Yaohui Ma, et al.
Published: (2022)

Cord blood antibody following maternal SARS-CoV-2 inactive vaccine (CoronaVac) administration during the pregnancy
by: Ahmet Soysal, et al.
Published: (2021)

Effectiveness of CoronaVac in preventing COVID-19 in healthcare workers
by: Gulsum Iclal Bayhan, et al.
Published: (2022)

Adverse events associated with CoronaVac in a university hospital
by: Lana N. SILVA-SANTOS, et al.
Published: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
by: Guy Cohen, et al.
Published: (2022)

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients
by: Michael Kwan Leung Yu, et al.
Published: (2024)

Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
by: Xiaoyin Zhang, et al.
Published: (2023)

Herpes zoster related hospitalization after inactivated (CoronaVac) and mRNA (BNT162b2) SARS-CoV-2 vaccination: A self-controlled case series and nested case-control study
by: Eric Yuk Fai Wan, PhD, et al.
Published: (2022)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023)

A preliminary study on the effectiveness of maternal to neonatal transfer of antibodies against SARS-CoV-2 in the women vaccinated with heterologous CoronaVac-ChAdOx1
by: Saipin Pongsatha, et al.
Published: (2023)

Risk of adverse events following CoronaVac's COVID-19 vaccination in women with and without autoimmunity
by: Stevent Sumantri, et al.
Published: (2023)

Effects of maternal antibodies in infants on the immunogenicity and safety of inactivated polio vaccine in infants
by: Shuyu Gao, et al.
Published: (2022)

Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study
by: Matt D.T. Hitchings, et al.
Published: (2021)

How has research on the effectiveness and safety of COVID-19 vaccination been evaluated: a scope review with emphasis on CoronaVac
by: Juan C. Alzate-Ángel, et al.
Published: (2024)

A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report
by: Nahide Onsun, et al.
Published: (2021)

Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
by: Thiago Cerqueira-Silva, et al.
Published: (2022)

Humoral immunity against SARS-CoV-2 evoked by heterologous vaccination groups using the CoronaVac (Sinovac) and BNT162b2 (Pfizer/BioNTech) vaccines in Chile
by: Diego A. Díaz-Dinamarca, et al.
Published: (2023)

Description of Symptoms Caused by the Infection of the SARS-CoV-2 B.1.621 (Mu) Variant in Patients With Complete CoronaVac Vaccination Scheme: First Case Report From Santiago of Chile
by: Carlos Barrera-Avalos, et al.
Published: (2022)

Comparative immunogenicity and neutralizing antibody responses post heterologous vaccination with CoronaVac (Sinovac) and Vaxzevria (AstraZeneca) in HIV-infected patients with varying CD4+ T lymphocyte counts
by: Sorawit Chittrakarn, et al.
Published: (2024)

Humoral anti-SARS-CoV-2 immune response for different strains after Sinovac-CoronaVac and Oxford/AstraZeneca (ChAdOx1-S) full vaccination on a healthcare population in Brazil
by: Maicon Jeferson Silva de Oliveira, et al.
Published: (2024)

Safety of BNT162b2 or CoronaVac COVID-19 vaccines in patients with heart failure: A self-controlled case series studyResearch in context
by: Xuxiao Ye, et al.
Published: (2023)

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-19 and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults
by: Suvimol Niyomnaitham, et al.
Published: (2022)

La aprobación de CoronaVac en Brasil y Chile: algunas lecciones sobre los retos regulatorios de vacunas
by: Ana Sojo
Published: (2022)

Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study
by: Angel Paternina-Caicedo, et al.
Published: (2022)

Neutralizing activity of a third dose of CoronaVac against Omicron subvariants within a 20-month follow-up study
by: Cheng Cao, et al.
Published: (2023)

Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series
by: Ting Zhao, et al.
Published: (2022)

How to Increase the Immunogenicity of SARS-COV-2 Inactivated Vaccines?
by: Yousef Khadivi
Published: (2021)

Immunogenicity and safety of two-dose or three-dose regimens of inactivated COVID-19 vaccines in patients with pulmonary tuberculosis: a randomised clinical trial
by: Pengfei Jin, et al.
Published: (2024)

Safety and immunogenicity of inactivated SARS-CoV-2 vaccine in high-risk occupational population: a randomized, parallel, controlled clinical trial
by: Yongliang Feng, et al.
Published: (2021)

AS03-adjuvanted H5N1 vaccine enhances immune response by modulating NR4A1, SDC1, ID3 genes, and reducing cortisol
by: Lairun Jin, et al.
Published: (2024)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
by: Shanshan Han, et al.
Published: (2023)

Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses
by: Diana Lourdes Padilla-Bórquez, et al.
Published: (2024)

Safety and immunogenicity of a novel quadrivalent subunit influenza vaccine in animal models
by: Huayue Ye, et al.
Published: (2020)

Evaluation of immunogenicity post two doses of inactivated SARS-CoV-2 vaccine, Covaxin after six months
by: Rima R. Sahay, et al.
Published: (2022)

Immunogenicity assessment of elder hepatocellular carcinoma patients after inactivated whole-virion SARS-CoV-2 vaccination
by: Ruyun Gao, et al.
Published: (2023)

Binding and neutralizing abilities of antibodies towards SARS-CoV-2 S2 domain
by: Xingsu Gao, et al.
Published: (2022)